Geron Corp
(NAS:GERN)
$
3.3
0 (0%)
Market Cap: 1.99 Bil
Enterprise Value: 1.74 Bil
PE Ratio: 0
PB Ratio: 6.73
GF Score: 37/100 Geron Corp at B Riley Securities Oncology Conference (Virtual) Transcript
Jan 18, 2023 / 06:00PM GMT
Release Date Price:
$3.12
(-1.58%)
Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst
All right. Good morning, everyone. Thank you for tuning in B. Riley's Oncology Conference. I'm Kalpit Patel, a research analyst here on the biotech team at B. Riley. Our next fireside chat is with a company called Geron, and we have the company's CEO, John Scarlett. Chip, thanks very much for joining us today.
Questions & Answers
Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst
Maybe we can get started with you had a major clearing event with imetelstat recently in lower-risk MDS. And maybe we can just start with your overall take on hitting the primary endpoint in IMerge. Were there any surprises relative to what you've seen in the Phase II, maybe both on the positive and on the negative sides of the equation?
John A. Scarlett
Geron Corporation - Chairman of the Board, President & CEO
Yes, sure. Thanks, Kalpit. I'll answer that question in a second. First of all,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot